Literature DB >> 7139903

Digoxin-quinidine interaction in patients with chronic renal failure.

P E Fenster, W D Hager, D Perrier, J R Powell, P E Graves, U F Michael.   

Abstract

We evaluated the effect of quinidine on digoxin pharmacokinetic in six patients with severe renal failure. Quinidine reduced the total body clearance of digoxin from 1.87 to 1.06 l/hour (p less than 0.001), and prolonged the digoxin half-life of elimination from 5.20 to 9.61 days (p less than 0.01). The digoxin volume of distribution was unchanged. Renal clearance of digoxin was negligible; thus, the decrease in total body clearance was due to a decrease in the nonrenal clearance of digoxin. The mean trough serum concentrations of quinidine ranged from 1.0 to 3.0 micrograms/ml. We conclude that in patients with chronic renal failure, the dose of digoxin should be decreased by 50% if quinidine therapy is initiated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7139903     DOI: 10.1161/01.cir.66.6.1277

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

Review 1.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 2.  Pharmacokinetic drug interactions between digoxin and antiarrhythmic agents and calcium channel blocking agents: an appraisal of study methodology.

Authors:  E M Antman; J M Arnold; P L Friedman; T W Smith
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

Review 3.  Differential pharmacokinetics of digoxin in elderly patients.

Authors:  C G Hanratty; P McGlinchey; G D Johnston; A P Passmore
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

Review 4.  Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.

Authors:  Kunal S Taskar; Xinning Yang; Sibylle Neuhoff; Mitesh Patel; Kenta Yoshida; Mary F Paine; Kim L R Brouwer; Xiaoyan Chu; Yuichi Sugiyama; Jack Cook; Joseph W Polli; Imad Hanna; Yurong Lai; Maciej Zamek-Gliszczynski
Journal:  Clin Pharmacol Ther       Date:  2022-06-22       Impact factor: 6.903

5.  Effects of decreased vitamin D and accumulated uremic toxin on human CYP3A4 activity in patients with end-stage renal disease.

Authors:  Masayuki Tsujimoto; Yui Nagano; Satomi Hosoda; Asuka Shiraishi; Ayaka Miyoshi; Shima Hiraoka; Taku Furukubo; Satoshi Izumi; Tomoyuki Yamakawa; Tetsuya Minegaki; Kohshi Nishiguchi
Journal:  Toxins (Basel)       Date:  2013-08-19       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.